Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Determine the Safety and Efficacy of a Combination of Green Tea and Quercetin With Docetaxel in Castration-resistant Prostate Cancer Patients

NCT06615752 is registered in ClinicalTrials.gov with Charles Drew University of Medicine and Science as lead sponsor.

NCT NCT06615752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06615752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Determine the Safety and Efficacy of a Combination of Green Tea and Quercetin With Docetaxel in Castration-resistant Prostate Cancer Patients
Lead sponsor
Charles Drew University of Medicine and Science
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 31, 2026
Completion date
February 28, 2029
Enrollment
99 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer (mcrpc)